INOVIO to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference
INOVIO (NASDAQ: INO), a biotechnology company specializing in DNA medicines for HPV-associated diseases, cancer, and infectious diseases, has announced its participation in the Oppenheimer 35th Annual Healthcare Life Sciences Conference.
The company's President and CEO, Dr. Jacqueline Shea, along with Chief Medical Officer Dr. Michael Sumner, will deliver a presentation on Wednesday, February 12, 2025, from 3:20 to 3:50 PM ET. The management team will also conduct one-on-one meetings with registered investors during the conference.
Interested parties can access the presentation through a webcast available on INOVIO's Investor Relations Events page, with replay access available for 90 days following the presentation.
INOVIO (NASDAQ: INO), un'azienda biotecnologica specializzata in medicine a base di DNA per malattie associate all'HPV, tumori e malattie infettive, ha annunciato la sua partecipazione alla 35a Conferenza Annuale sulla Salute e le Scienze della Vita organizzata da Oppenheimer.
Il Presidente e CEO dell'azienda, Dr. Jacqueline Shea, insieme al Direttore Medico Dr. Michael Sumner, presenterà un intervento mercoledì 12 febbraio 2025, dalle 15:20 alle 15:50 (ET). Il team dirigenziale condurrà anche incontri individuali con gli investitori registrati durante la conferenza.
Le parti interessate possono accedere alla presentazione tramite una trasmissione web disponibile sulla pagina Eventi delle Relazioni con gli Investitori di INOVIO, con accesso alle registrazioni disponibile per 90 giorni dopo la presentazione.
INOVIO (NASDAQ: INO), una empresa biotecnológica especializada en medicamentos basados en ADN para enfermedades asociadas con el VPH, cáncer y enfermedades infecciosas, ha anunciado su participación en la 35ª Conferencia Anual sobre Ciencias de la Salud de Oppenheimer.
La Presidenta y CEO de la empresa, Dra. Jacqueline Shea, junto con el Director Médico Dr. Michael Sumner, realizará una presentación el miércoles 12 de febrero de 2025, de 3:20 a 3:50 PM ET. El equipo directivo también llevará a cabo reuniones individuales con inversores registrados durante la conferencia.
Las partes interesadas pueden acceder a la presentación a través de una retransmisión disponible en la página de Eventos de Relaciones con Inversores de INOVIO, con acceso a la repetición disponible durante 90 días después de la presentación.
INOVIO (NASDAQ: INO)은 HPV 관련 질병, 암, 감염성 질병을 위한 DNA 의약품을 전문으로 하는 생명공학 회사로, 오펜하이머 제35회 연례 헬스케어 생명과학 컨퍼런스에 참가한다고 발표했습니다.
회사의 회장 겸 CEO인 Dr. Jacqueline Shea와 최고 의료 책임자인 Dr. Michael Sumner이 2025년 2월 12일 수요일, 오후 3:20부터 3:50 PM ET까지 발표를 진행할 예정입니다. 경영진은 또한 컨퍼런스 기간 동안 등록된 투자자들과 일대일 회의를 진행할 것입니다.
관심 있는 분들은 INOVIO의 투자자 관계 이벤트 페이지에서 웹캐스트를 통해 발표를 접근할 수 있으며, 발표 후 90일 동안 재생 접근이 가능합니다.
INOVIO (NASDAQ: INO), une entreprise biopharmaceutique spécialisée dans les médicaments à base d'ADN pour les maladies associées au VPH, le cancer et les maladies infectieuses, a annoncé sa participation à la 35e Conférence Annuelle sur les Sciences de la Vie et la Santé d'Oppenheimer.
La Présidente et CEO de l'entreprise, Dr. Jacqueline Shea, ainsi que le médecin-chef Dr. Michael Sumner, donneront une présentation le mercredi 12 février 2025, de 15h20 à 15h50 (ET). L'équipe de direction effectuera également des réunions individuelles avec des investisseurs inscrits pendant la conférence.
Les parties intéressées peuvent accéder à la présentation via un webinaire disponible sur la page des événements des relations avec les investisseurs d'INOVIO, avec un accès à la rediffusion pendant 90 jours après la présentation.
INOVIO (NASDAQ: INO), ein biotechnologisches Unternehmen, das sich auf DNA-Medikamente für HPV-assoziierte Krankheiten, Krebs und Infektionskrankheiten spezialisiert hat, hat seine Teilnahme an der 35. Jahreskonferenz für Gesundheits- und Life Sciences von Oppenheimer bekannt gegeben.
Die Präsidentin und CEO des Unternehmens, Dr. Jacqueline Shea, zusammen mit dem Chief Medical Officer Dr. Michael Sumner, wird am Mittwoch, den 12. Februar 2025, von 15:20 bis 15:50 Uhr ET eine Präsentation halten. Das Management-Team wird während der Konferenz auch Einzelgespräche mit registrierten Investoren führen.
Interessierte Parteien können die Präsentation über ein Webcast auf der Seite für Investor Relations von INOVIO zugreifen, wobei die Wiederholung für 90 Tage nach der Präsentation verfügbar ist.
- None.
- None.
Oppenheimer 35th Annual Healthcare Life Sciences Conference
Date: Wednesday, February 12, 2025
Time: 3:20 – 3:50 pm ET
Format: Presentation
During the conference, Dr. Shea and members of INOVIO's management team will conduct one-on-one meetings with registered investors.
A webcast of the presentation will be available on the INOVIO Investor Relations Events page at https://ir.inovio.com/events-and-presentations/default.aspx. A replay of the webcast will be available for 90 days after the date of the presentation.
About INOVIO
INOVIO is a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases. INOVIO's technology optimizes the design and delivery of innovative DNA medicines that teach the body to manufacture its own disease-fighting tools. For more information, visit www.inovio.com.
Contacts
Media: Jennie Willson, (267) 429-8567, communications@inovio.com
Investors: Peter Vozzo, ICR Healthcare, 443-213-0505, investor.relations@inovio.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/inovio-to-participate-in-the-oppenheimer-35th-annual-healthcare-life-sciences-conference-302363750.html
SOURCE INOVIO Pharmaceuticals, Inc.
FAQ
When is INOVIO presenting at the Oppenheimer Healthcare Conference 2025?
How can investors watch INOVIO's Oppenheimer Conference presentation?
Who will be representing INOVIO at the 2025 Oppenheimer Conference?
Will INOVIO management be available for investor meetings at the Oppenheimer Conference?
